Navigation Links
Vermillion Attends 42nd Annual Meeting of the Society of Gynecologic Oncologists

AUSTIN, Texas, March 7, 2011 /PRNewswire/ -- (Nasdaq: VRML) -- Vermillion is pleased to announce the presentation of two studies demonstrating the high sensitivity of OVA1® during the 42nd Annual Meeting on Women's Cancer of the Society of Gynecologic Oncologists, March 6-9, 2011 in Orlando, Florida.  The presentations were as follows:

  • Rachel, W. Miller, MD, Clinical Fellow in the Department of Gynecologic  Oncology, University of Kentucky Healthcare Markey Cancer Center"OVA1 improves the sensitivity of the ACOG referral guidelines for an ovarian mass"Dr. Miller's presentation reported the performance of the current ACOG guidelines and the modified ACOG criteria in the prospective multi-center OVA1 clinical trial.  Replacing CA125 with OVA1 in these guidelines would have improved overall sensitivity for ovarian malignancy from 77% to 94%. This improvement held across both pre- and postmenopausal women and all stages of malignancy. In particular, sensitivity for malignancy among premenopausal women improved from 58% to 91% and from 47% to 88% for premenopausal women with early stage ovarian cancer.

  • Fred Ueland, M.D., Associate Professor of Gynecologic Oncology at the University of Kentucky's Markey Cancer Center, and principal investigator of the multi-center OVA1 clinical trial, and Dr. Zhen Zhang from the Department of Pathology of Johns Hopkins Medical Institutions"OVA1 Has High Sensitivity in Identifying Ovarian Malignancy Compared to Preoperative Assessment and CA125"Dr. Ueland and Dr. Zhang's presentation evaluated subjects enrolled in the prospective OVA1 clinical trial.  The physician's pre-operative assessment resulted in a sensitivity of 75.2% which would have improved significantly to 95.7% with the addition of OVA1.  Dr. Ueland and Dr. Zhang conclude that "when combined with a preoperative assessment, OVA1 can help determine the risk of malignancy for an ovarian tumor before surgery, and facilitate decisions about referral to a gynecologic oncologist."  "These additional data provide further support for the clinical utility of OVA1," stated Eric T. Fung, MD, PhD. Vermillion's Senior Vice president and Chief Science Officer.  "In particular, when OVA1 is used as part of a comprehensive workup per ACOG/SGO recommendations, sensitivity for ovarian malignancy may increase substantially."

    About VermillionVermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health.  Additional information about Vermillion can be found on the Web at

    About OVA1®OVA1® is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers - Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), beta 2-Microglobulin (beta 2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) - and a proprietary FDA-cleared software device to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.  Additional information about OVA1® can be found on the Web at

    Forward-Looking StatementCertain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its future products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.  

    This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q.  Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at


  • SOURCE Vermillion, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Vermillion to Present at the Roth 23rd Annual OC Growth Stock Conference March 13-16, 2011, Laguna Niguel, CA
    2. Vermillion Announces $21.8 Million Public Offering
    3. Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Fourth Quarter 2010
    4. Vermillion Announces Issuance of Patent for Peripheral Artery Disease
    5. Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm
    6. Vermillion Reports Financial Results for the Third Quarter 2010
    7. Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Second Quarter 2010
    8. Vermillion Announces Relocation of Corporate Offices to Austin, Texas
    9. Vermillion Announces Issuance of Patent for Alzheimers Disease Diagnosis
    10. Vermillion to Present at the Roth 22nd Annual OC Growth Stock Conference March 15 - 17, Laguna Niguel, CA
    11. Vermillion Adds Peter S. Roddy to Board and Provides Corporate Update
    Post Your Comments:
    (Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Italian Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
    (Date:11/25/2015)... global healthcare industry is expected to grow at a rate ... has the highest projected growth at 12.7%, and ... is second with growth projected at 11.5%. ... 2013-2014, total government funded healthcare was nearly 68%. Federal government ... 2013-2014. In real terms, out of pocket expenditure increased by ...
    (Date:11/25/2015)... , Nov. 25, 2015 AAIPharma ... planned investment of at least $15.8  Million to ... Wilmington, NC . The expansion will ... to meet the growing demands of the pharmaceutical ... site expansion will provide up to 40,000 ...
    Breaking Medicine Technology:
    (Date:11/27/2015)... PITTSBURGH, PA (PRWEB) , ... November 27, 2015 ... ... of how filthy the toilets were," said an inventor from Hillside, N.J. "Many ... this improved seat cover so that individuals will always be protected from germs." ...
    (Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of the ... 2016, at Caesars Palace in Las Vegas with a pre-conference session on a ...
    (Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud ... Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is ... only one of twelve colleges and universities in the state of California make the ...
    (Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
    (Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical laboratories and in ... by healthcare staffing agency Aureus Medical Group . These fields, as ... among those searching for healthcare jobs through the company’s website, , ...
    Breaking Medicine News(10 mins):